|
|
|
|
|
|
|
Mon T W Th F |
|
12 October, 2026 |
|
|
sponsored by
|
|
|
|
Delegate the Groundwork. Free Your Schedule to Advance the Science.
|
| Are you losing days chasing records across systems and assembling evidence before an investigation can begin? Katalyze AI delegates the groundwork to agents that gather the evidence and draft reports for you, with every finding connected back to its source. You review the results, challenge them in plain language, and decide what happens next. Built for GxP environments, Katalyze offers solutions for Yield Optimization, Deviation Investigation, Tech Transfer, and Raw Material Characterization. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Merck has been hungry to expand its pipeline ahead of Keytruda’s upcoming patent cliff. But as BMO analysts spelled out on Sunday, “not all BD deals become winners.” It appears that might be the case for remigromig, an eye candidate Merck acquired in its $1.3 billion upfront deal for EyeBio. I wrote about remigromig’s mixed pivotal readout here. In the meantime, we’ll be keeping an eye on other prospects in Merck’s late-stage pipeline. |
|
|
|
Nicole DeFeudis |
Senior Reporter, Endpoints News
@Nicole_DeFeudis
|
|
|
|
|
|
|
by Nicole DeFeudis
|
Merck’s ophthalmology candidate, remigromig, met the primary endpoint in a pivotal study, but the full results raise questions about the drug’s commercial prospects. Merck said... | |
|
|
|
|
|
|
by Max Bayer
|
Japanese pharma Asahi Kasei Therapeutics has snagged FDA approval for a herpes treatment that it acquired early this year in an almost $1 billion deal... | |
|
|
|
|
|
|
|
|
by Andrew Dunn
|
Brent Saunders, one of biopharma’s most prominent dealmakers and highest-paid leaders, is out as CEO of Bausch + Lomb, failing to add another multibillion-dollar company... | |
|
|
|
|
|
|
by Anna Brown
|
GSK has budgeted more than $800 million to grow its Pennsylvania footprint, its second expansion in the state in two years. The company will... | |
|
|
|
|
|
|
by Max Gelman
|
Bristol Myers Squibb reported two Phase 3 successes on Monday morning, including for an experimental drug that recently ran into safety issues. A trial testing... | |
|
|
|
|
|
|
by Ayisha Sharma
|
New details from AstraZeneca's failed Phase 3 trial of its enzyme replacement therapy for a genetic bone disease suggest the study missed its goals because... | |
|
|
|
|
|
